The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: Study protocol for a randomised controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Nazir, Sheraz A ^a   Khan, Jamal N ^a   Mahmoud, Islam Z ^b   Greenwood, John P ^c   Blackman, Daniel J ^c   Kunadian, Vijay ^d   Been, Martin ^e   Abrams, Keith R ^f   Wilcox, Robert ^g   Adgey, AA J ^h   McCann, Gerry P ^a   Gershlick, Anthony H ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

^g QUEEN S MEDICAL CENTRE   (United Kingdom)

^h ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Adenosine; Cardiovascular magnetic resonance; Microvascular obstruction; Myocardial infarction; Nitroprusside; Primary angioplasty

Indexed keywords

ADENOSINE; HIRULOG; NITROPRUSSIDE SODIUM; VASODILATOR AGENT;

ADULT; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ARTICLE; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HUMAN; INTRACORONARY DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MICROVASCULAR OBSTRUCTION; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBUS ASPIRATION; TREATMENT OUTCOME; ADVERSE EFFECTS; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY BLOOD VESSEL; DRUG EFFECTS; METHODOLOGY; MICROCIRCULATION; MYOCARDIAL INFARCTION; MYOCARDIAL PERFUSION IMAGING; NO-REFLOW PHENOMENON; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; REPERFUSION INJURY; TIME; UNITED KINGDOM;

ADENOSINE; CLINICAL PROTOCOLS; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CORONARY VESSELS; GREAT BRITAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MICROCIRCULATION; MYOCARDIAL INFARCTION; MYOCARDIAL PERFUSION IMAGING; NITROPRUSSIDE; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; REPERFUSION INJURY; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84908140852     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-371     Document Type: Article

References (119)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13-20. 10.1016/S0140-6736(03)12113-7, 12517460.
2. Kloner RA, Ganote CE, Jennings RB. The " no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974, 54:1496-1508. 10.1172/JCI107898, 301706, 4140198.
3. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword?. J Clin Invest 1985, 76:1713-1719. 10.1172/JCI112160, 424191, 4056048.
4. Harlan JM. Leukocyte-endothelial interactions. Blood 1985, 65:513-525.
5. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985, 312:159-163. 10.1056/NEJM198501173120305, 2981404.
6. Engler R, Covell JW. Granulocytes cause reperfusion ventricular dysfunction after 15-minute ischemia in the dog. Circ Res 1987, 61:20-28. 10.1161/01.RES.61.1.20, 3038366.
7. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000, 101:570-580. 10.1161/01.CIR.101.5.570, 10662756.
8. Gersh BJ. Optimal management of acute myocardial infarction at the dawn of the next millennium. Am Heart J 1999, 138:S188-S202. 10.1016/S0002-8703(99)70342-X, 10426881.
9. Kotani J, Nanto S, Mintz GS, Kitakaze M, Ohara T, Morozumi T, Nagata S, Hori M. Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation 2002, 106:1672-1677. 10.1161/01.CIR.0000030189.27175.4E, 12270861.
10. Araszkiewicz A, Grajek S, Lesiak M, Prech M, Pyda M, Janus M, Cieslinski A. Effect of impaired myocardial reperfusion on left ventricular remodeling in patients with anterior wall acute myocardial infarction treated with primary coronary intervention. Am J Cardiol 2006, 98:725-728. 10.1016/j.amjcard.2006.04.009, 16950171.
11. Galiuto L, Lombardo A, Maseri A, Santoro L, Porto I, Cianflone D, Rebuzzi AG, Crea F. Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation. Heart 2003, 89:731-737. 10.1136/heart.89.7.731, 1767736, 12807843.
12. Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol 2010, 23:429-436. 10.1111/j.1540-8183.2010.00561.x, 20819117.
13. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998, 97:765-772. 10.1161/01.CIR.97.8.765, 9498540.
14. Wu KC, Kim RJ, Bluemke DA, Rochitte CE, Zerhouni EA, Becker LC, Lima JA. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol 1998, 32:1756-1764. 10.1016/S0735-1097(98)00429-X, 9822106.
15. Hombach V, Grebe O, Merkle N, Waldenmaier S, Höher M, Kochs M, Wöhrle J, Kestler H. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J 2005, 26:549-557.
16. Nijveldt R, Beek AM, Hirsch A, Stoel MG, Hofman MB, Umans VA, Algra PR, Twisk JW, van Rossum AC. Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Cardiol 2008, 52:181-189. 10.1016/j.jacc.2008.04.006, 18617066.
17. Vlaar PJ, Svilaas T, van der Horst IC, Diercks GF, Fokkema ML, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 2008, 371:1915-1920. 10.1016/S0140-6736(08)60833-8, 18539223.
18. Sardella G, Mancone M, Bucciarelli-Ducci C, Agati L, Scardala R, Carbone I, Francone M, Di Roma A, Benedetti G, Conti G, Fedele F. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol 2009, 53:309-315. 10.1016/j.jacc.2008.10.017, 19161878.
19. Liistro F, Grotti S, Angioli P, Falsini G, Ducci K, Baldassarre S, Sabini A, Brandini R, Capati E, Bolognese L. Impact of thrombus aspiration on myocardial tissue reperfusion and left ventricular functional recovery and remodeling after primary angioplasty. Circ Cardiovasc Interv 2009, 2:376-383. 10.1161/CIRCINTERVENTIONS.109.852665, 20031746.
20. Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink J-HE, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, . Gibson CM; INFUSE-AMI Investigators Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 2012, 307:1817-1826. 10.1001/jama.2012.421, 22447888, Gibson CM; INFUSE-AMI Investigators.
21. Dudek D, Mielecki W, Burzotta F, Gasior M, Witkowski A, Horvath IG, Legutko J, Ochala A, Rubartelli P, Wojdyla RM, Siudak Z, Buchta P, Pregowski J, Aradi D, Machnik A, Hawranek M, Rakowski T, Dziewierz A, Zmudka K. Thrombus aspiration followed by direct stenting: a novel strategy of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. Results of the Polish-Italian-Hungarian RAndomized ThrombEctomy Trial (PIHRATE Trial). Am Heart J 2010, 160:966-972. 10.1016/j.ahj.2010.07.024, 21095287.
22. Frobert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, Aasa M, Angeras O, Calais F, Danielewicz M, Erlinge D, Hellsten L, Jensen U, Johannson AC, Karegren A, Nilsson J, Robertson L, Sandhall L, Sjogren I, Ostlund O, Harnek J, James SK, . TASTE Trial Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 2013, 369:1587-1597. 10.1056/NEJMoa1308789, 23991656, TASTE Trial.
23. Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008, 358:557-567. 10.1056/NEJMoa0706416, 18256391.
24. Tomassini F, Gagnor A, Montali N, Gambino A, Bollati M, Infantino V, Rigattieri S, Varbella F. Impact of thrombus aspiration during primary percutaneous coronary intervention in cardiogenic shock complicating ST-segment elevation myocardial infarction. Cardiovasc Revasc Med 2013, 14:307-310. 10.1016/j.carrev.2013.08.006, 24075314.
25. Kumbhani DJ, Bavry AA, Desai MY, Bangalore S, Bhatt DL. Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. J Am Coll Cardiol 2013, 62:1409-1418. 10.1016/j.jacc.2013.04.025, 23665372.
26. De Luca G, Navarese EP, Suryapranata H. A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol 2013, 166:606-612. 10.1016/j.ijcard.2011.11.102, 22284272.
27. Jolly SS, Cairns J, Yusuf S, Meeks B, Shestakovska O, Thabane L, Niemela K, Steg PG, Bertrand OF, Rao SV, Avezum A, Cantor WJ, Pancholy SB, Moreno R, Gershlick A, Bhindi R, Welsh RC, Cheema AN, Lavi S, Rokoss M, Dsavik V. Design and rationale of the TOTAL trial: a randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI. Am Heart J 2014, 167:315-321. 10.1016/j.ahj.2013.12.002, 24576514.
28. Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008, 118:49-57. 10.1161/CIRCULATIONAHA.107.747642, 18559698.
29. Bartorelli AL, Trabattoni D, Galli S, Grancini L, Cozzi S, Ravagnani P. Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA. Catheter Cardiovasc Interv 1999, 48:211-213. 10.1002/(SICI)1522-726X(199910)48:2<211::AID-CCD20>3.0.CO;2-V, 10506783.
30. Kakkar AK, Moustapha A, Hanley HG, Weiss M, Caldito G, Misra P, Reddy PC, Tandon N. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv 2004, 61:31-34. 10.1002/ccd.10730, 14696156.
31. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM, . ACUITY Investigators Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006, 355:2203-2216. 10.1056/NEJMoa062437, 17124018, ACUITY Investigators.
32. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R, . HORIZONS-AMI Trial Investigators Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008, 358:2218-2230. 10.1056/NEJMoa0708191, 18499566, HORIZONS-AMI Trial Investigators.
33. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, Sakai K. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J 1996, 132:959-963. 10.1016/S0002-8703(96)90005-8, 8892767.
34. Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FV, Grines CL, O'Neill WW, Safian RD. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1996, 39:113-118. 10.1002/(SICI)1097-0304(199610)39:2<113::AID-CCD1>3.0.CO;2-I, 8922307.
35. Kloner RA, Alker KJ. The effect of streptokinase on intramyocardial hemorrhage, infarct size, and the no-reflow phenomenon during coronary reperfusion. Circulation 1984, 70:513-521. 10.1161/01.CIR.70.3.513, 6744555.
36. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002, 57:444-451. 10.1002/ccd.10375, 12455077.
37. Weyrens FJ, Mooney J, Lesser J, Mooney MR. Intracoronary diltiazem for microvascular spasm after interventional therapy. Am J Cardiol 1995, 75:849-850. 10.1016/S0002-9149(99)80430-5, 7717298.
38. Rawitscher D, Levin TN, Cohen I, Feldman T. Rapid reversal of no-reflow using Abciximab after coronary device intervention. Cathet Cardiovasc Diagn 1997, 42:187-190. 10.1002/(SICI)1097-0304(199710)42:2<187::AID-CCD20>3.0.CO;2-K, 9328705.
39. Skelding KA, Goldstein JA, Mehta L, Pica MC, O'Neill WW. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv 2002, 57:305-309. 10.1002/ccd.10303, 12410503.
40. Ota S, Nishikawa H, Takeuchi M, Nakajima K, Nakamura T, Okamoto S, Setsuda M, Makino K, Yamakado T, Nakano T. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J 2006, 70:1099-1104. 10.1253/circj.70.1099, 16936418.
41. Kunadian V, Zorkun C, Williams SP, Biller LH, Palmer AM, Ogando KJ, Lew ME, Nethala N, Gibson WJ, Marble SJ, Buros JL, Gibson CM. Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction. J Thromb Thrombolysis 2008, 26:234-242. 10.1007/s11239-008-0276-0, 18818881.
42. Amit G, Cafri C, Yaroslavtsev S, Fuchs S, Paltiel O, Abu-Ful A, Weinstein JM, Wolak A, Ilia R, Zahger D. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J 2006, 152:887.e9-14.
43. Kobatake R, Sato T, Fujiwara Y, Sunami H, Yoshioka R, Ikeda T, Saito H, Ujihira T. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart Vessels 2011, 26:379-384. 10.1007/s00380-010-0065-5, 21110199.
44. Niccoli G, Rigattieri S, De Vita MR, Valgimigli M, Corvo P, Fabbiocchi F, Romagnoli E, De Caterina AR, La Torre G, Lo Schiavo P, Tarantino F, Ferrari R, Tomai F, Olivares P, Cosentino N, D'Amario D, Leone AM, Porto I, Burzotta F, Trani C, Crea F. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). JACC Cardiovasc Interv 2013, 6:580-589. 10.1016/j.jcin.2013.02.009, 23683738.
45. Parikh KH, Chag MC, Shah KJ, Shah UG, Baxi HA, Chandarana AH, Naik AM, Shah JN, Shah HD, Goyal RK. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol 2007, 85:476-482. 10.1139/Y07-013, 17612657.
46. Pasceri V, Pristipino C, Pelliccia F, Granatelli A, Speciale G, Roncella A, Pironi B, Capasso M, Richichi G. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol 2005, 95:1358-1361. 10.1016/j.amjcard.2005.01.082, 15904643.
47. Shinozaki N, Ichinose H, Yahikozawa K, Shimada H, Hoshino K. Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction. Int Heart J 2007, 48:423-433. 10.1536/ihj.48.423, 17827814.
48. Wang HJ, Lo PH, Lin JJ, Lee H, Hung JS. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv 2004, 63:171-176. 10.1002/ccd.20149, 15390241.
49. Youssef AA, Wu CJ, Hang CL, Cheng CI, Yang CH, Chen CJ, Chen YH, Chai HT, Chua S, Yeh KH, Yip HK. Impact of PercuSurge device conjugative with intracoronary administration of nitroprusside on no-reflow phenomenon following primary percutaneous coronary intervention. Circ J 2006, 70:1538-1542. 10.1253/circj.70.1538, 17127795.
50. Claeys MJ, Bosmans J, De Ceuninck M, Beunis A, Vergauwen W, Vorlat A, Vrints CJ. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol 2004, 94:9-13.
51. Desmet W, Bogaert J, Dubois C, Sinnaeve P, Adriaenssens T, Pappas C, Ganame J, Dymarkowski S, Janssens S, Belmans A, Van de Werf F. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J 2011, 32:867-877. 10.1093/eurheartj/ehq492, 21196444.
52. Fokkema ML, Vlaar PJ, Vogelzang M, Gu YL, Kampinga MA, de Smet BJ, Jessurun GA, Anthonio RL, van den Heuvel AF, Tan ES, Zijlstra F. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ Cardiovasc Interv 2009, 2:323-329. 10.1161/CIRCINTERVENTIONS.109.858977.109.858977, 20031735.
53. Grygier M, Araszkiewicz A, Lesiak M, Janus M, Kowal J, Skorupski W, Pyda M, Mitkowski P, Grajek S. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2011, 107:1131-1135. 10.1016/j.amjcard.2010.12.010, 21310372.
54. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999, 34:1711-1720. 10.1016/S0735-1097(99)00418-0, 10577561.
55. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000, 101:2154-2159. 10.1161/01.CIR.101.18.2154, 10801755.
56. Micari A, Belcik TA, Balcells EA, Powers E, Wei K, Kaul S, Lindner JR. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol 2005, 96:1410-1415. 10.1016/j.amjcard.2005.06.090, 16275189.
57. Petronio AS, De Carlo M, Ciabatti N, Amoroso G, Limbruno U, Palagi C, Di Bello V, Romano MF, Mariani M. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J 2005, 150:1015.
58. Quintana M, Hjemdahl P, Sollevi A, Kahan T, Edner M, Rehnqvist N, Swahn E, Kjerr AC, Nasman P. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol 2003, 59:1-9.
59. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005, 45:1775-1780. 10.1016/j.jacc.2005.02.061, 15936605.
60. Stoel MG, Marques KM, de Cock CC, Bronzwaer JG, von Birgelen C, Zijlstra F. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: A randomized placebo-controlled pilot study. Catheter Cardiovasc Interv 2008, 71:283-289.
61. Zhang H, Tian NL, Hu ZY, Wang F, Chen L, Zhang YJ, Chen SL. Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction. Chin Med J (Engl) 2012, 125:1713-1719.
62. Vijayalakshmi K, Whittaker VJ, Kunadian B, Graham J, Wright RA, Hall JA, Sutton A, de Belder MA. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart 2006, 92:1278-1284. 10.1136/hrt.2005.075077, 1861197, 16449518.
63. Berne RM. The role of adenosine in the regulation of coronary blood flow. Circ Res 1980, 47:807-813. 10.1161/01.RES.47.6.807, 6254686.
64. Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol 2010, 185:1993-1998. 10.4049/jimmunol.1000108, 3036969, 20686167.
65. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001, 41:775-787. 10.1146/annurev.pharmtox.41.1.775, 11264476.
66. Olafsson B, Forman MB, Puett DW, Pou A, Cates CU, Friesinger GC, Virmani R. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 1987, 76:1135-1145. 10.1161/01.CIR.76.5.1135, 3664998.
67. Bates JN, Baker MT, Guerra R, Harrison DGDG. Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem Pharmacol 1991, 42(Suppl):S157-S165.
68. Gavin JB, Maxwell L, Edgar SG. Microvascular involvement in cardiac pathology. J Mol Cell Cardiol 1998, 30:2531-2540. 10.1006/jmcc.1998.0824, 9990524.
69. Pemberton M, Anderson GL, Barker JH. Characterization of microvascular vasoconstriction following ischemia/reperfusion in skeletal muscle using videomicroscopy. Microsurgery 1996, 17:9-16. 10.1002/(SICI)1098-2752(1996)17:1<9::AID-MICR2>3.0.CO;2-K, 8892274.
70. Wang WZ, Anderson G, Fleming JT, Peter FW, Franken RJ, Acland RD, Barker J. Lack of nitric oxide contributes to vasospasm during ischemia/reperfusion injury. Plast Reconstr Surg 1997, 99:1099-1108. 10.1097/00006534-199704000-00028, 9091909.
71. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 2006, 27:2400-2405. 10.1093/eurheartj/ehl094, 16782719.
72. Masci PG, Ganame J, Francone M, Desmet W, Lorenzoni V, Iacucci I, Barison A, Carbone I, Lombardi M, Agati L, Janssens S, Bogaert J. Relationship between location and size of myocardial infarction and their reciprocal influences on post-infarction left ventricular remodelling. Eur Heart J 2011, 32:1640-1648. 10.1093/eurheartj/ehr064, 21398642.
73. Aung Naing K, Li L, Su Q, Wu T. Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev 2013, 6:CD009503.
74. Kelly DJ, McCann GP, Blackman D, Curzen NP, Dalby M, Greenwood JP, Fairbrother K, Shipley L, Kelion A, Heatherington S, Khan JN, Nazir S, Alahmar A, Flather M, Swanton H, Schofield P, Gunning M, Hall R, Gershlick AH. Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design. EuroIntervention 2013, 8:1190-1198. 10.4244/EIJV8I10A183, 23425543.
75. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F, . STREAM Investigative Team Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013, 368:1379-1387. 10.1056/NEJMoa1301092, 23473396, STREAM Investigative Team.
76. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, . TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015. 10.1056/NEJMoa0706482, 17982182, TRITON-TIMI 38 Investigators.
77. National Institute for Health and Care Excellence Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention 2009, London: NICE, http://www.nice.org.uk/guidance/ta182, National Institute for Health and Care Excellence.
78. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009, 157:599-605. 10.1016/j.ahj.2009.01.003, 19332184.
79. European Society of Cardiology ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation 2009, Sophia Antipolis: ESC, http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/Guidelines_AMI_STEMI.pdf 2012 (accessed 15th January 2014), European Society of Cardiology.
80. National Institute for Health and Care Excellence Acute coronary syndromes - ticagrelor: guidance 2011, London: NICE, http://www.nice.org.uk/guidance/ta236, National Institute for Health and Care Excellence.
81. Schroder R, Dissmann R, Bruggemann T, Wegscheider K, Linderer T, Tebbe U, Neuhaus KL. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994, 24:384-391. 10.1016/0735-1097(94)90292-5, 8034872.
82. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van De Werf F, Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000, 101:125-130. 10.1161/01.CIR.101.2.125, 10637197.
83. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002, 105:1909-1913. 10.1161/01.CIR.0000014683.52177.B5, 11997276.
84. Vogelzang M, Vlaar PJ, Svilaas T, Amo D, Nijsten MW, Zijlstra F. Computer-assisted myocardial blush quantification after percutaneous coronary angioplasty for acute myocardial infarction: a substudy from the TAPAS trial. Eur Heart J 2009, 30:594-599. 10.1093/eurheartj/ehn542, 19168868.
85. Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996, 93:879-888. 10.1161/01.CIR.93.5.879, 8598078.
86. Kunadian V, Harrigan C, Zorkun C, Palmer AM, Ogando KJ, Biller LH, Lord EE, Williams SP, Lew ME, Ciaglo LN, Buros JL, Marble SJ, Gibson WJ, Gibson CM. Use of the TIMI frame count in the assessment of coronary artery blood flow and microvascular function over the past 15 years. J Thromb Thrombolysis 2009, 27:316-328. 10.1007/s11239-008-0220-3, 18425623.
87. Collaborators TIMI. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985, 312:932-936.
88. van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998, 97:2302-2306. 10.1161/01.CIR.97.23.2302, 9639373.
89. Yuval R, Halon DA, Merdler A, Khader N, Karkabi B, Uziel K, Lewis BS. Patient comprehension and reaction to participating in a double-blind randomized clinical trial (ISIS-4) in acute myocardial infarction. Arch Intern Med 2000, 160:1142-1146. 10.1001/archinte.160.8.1142, 10789607.
90. Williams BF, French JK, White HD, . HERO-2 consent substudy investigators Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study. Lancet 2003, 361:918-922. 10.1016/S0140-6736(03)12773-0, 12648970, HERO-2 consent substudy investigators.
91. Ibrahim T, Hackl T, Nekolla SG, Breuer M, Feldmair M, Schömig A. Acute myocardial infarction: serial cardiac MR imaging shows a decrease in delayed enhancement of the myocardium during the 1st week after reperfusion. Radiology 2010, 254:88-97. 10.1148/radiol.09090660, 20032144.
92. Albert TSE, Kim RJ, Judd RM. Assessment of no-reflow regions using cardiac MRI. Basic Res Cardiol 2006, 101:383-390. 10.1007/s00395-006-0617-0, 16915529.
93. Tilak GS, Hsu LY, Hoyt RF, Arai AE, Aletras AH. In vivo T2-weighted magnetic resonance imaging can accurately determine the ischemic area at risk for 2-day-old nonreperfused myocardial infarction. Invest Radiol 2008, 43:7-15. 10.1097/RLI.0b013e3181558822, 18097272.
94. Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy 2002, 22:105S-111S. 10.1592/phco.22.10.105S.33616, 12064567.
95. Cortese B, Picchi A, Micheli A, Limbruno U. Intracoronary bivalirudin for no reflow reversal: a second chance to treat this disorder?. J Thromb Thrombolysis 2009, 28:74-76. 10.1007/s11239-008-0243-9, 18597045.
96. Bertomeu-Gonzalez V, Bodi V, Sanchis J, Nunez J, Lopez-Lereu MP, Pena G, Losada A, Gomez C, Chorro FJ, Llacer A. [Limitations of myocardial blush grade in the evaluation of myocardial perfusion in patients with acute myocardial infarction and TIMI grade 3 flow]. Rev Esp Cardiol 2006, 59:575-581.
97. Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V, Moon JC. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging 2011, 4:150-156. 10.1016/j.jcmg.2010.11.015, 21329899.
98. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985, 5:587-592. 10.1016/S0735-1097(85)80380-6, 3156171.
99. Bello D, Einhorn A, Kaushal R, Kenchaiah S, Raney A, Fieno D, Narula J, Goldberger J, Shivkumar K, Subacius H, Kadish A. Cardiac magnetic resonance imaging: infarct size is an independent predictor of mortality in patients with coronary artery disease. Magn Reson Imaging 2011, 29:50-56. 10.1016/j.mri.2010.03.031, 20980115.
100. Eitel I, Desch S, de Waha S, Fuernau G, Gutberlet M, Schuler G, Thiele H. Long-term prognostic value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. Heart 2011, 97:2038-2045. 10.1136/heartjnl-2011-300098, 21990384.
101. Ezekowitz JA, Armstrong PW, Granger CB, Theroux P, Stebbins A, Kim RJ, Patel MR. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. Am Heart J 2010, 160:272-278. 10.1016/j.ahj.2010.05.035, 20691832.
102. Ganame J, Messalli G, Dymarkowski S, Rademakers FE, Desmet W, Van de Werf F, Bogaert J. Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. Eur Heart J 2009, 30:1440-1449. 10.1093/eurheartj/ehp093, 19346229.
103. Gerber BL. Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation 2002, 106:1083-1089. 10.1161/01.CIR.0000027818.15792.1E, 12196333.
104. Kelle S, Roes SD, Klein C, Kokocinski T, de Roos A, Fleck E, Bax JJ, Nagel E. Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J Am Coll Cardiol 2009, 54:1770-1777. 10.1016/j.jacc.2009.07.027, 19874990.
105. Klem I, Shah DJ, White RD, Pennell DJ, van Rossum AC, Regenfus M, Sechtem U, Schvartzman PR, Hunold P, Croisille P, Parker M, Judd RM, Kim RJ. Prognostic value of routine cardiac magnetic resonance assessment of left ventricular ejection fraction and myocardial damage: an international, multicenter study. Circ Cardiovasc Imaging 2011, 4:610-619.
106. Kwong RY, Chan AK, Brown KA, Chan CW, Reynolds HG, Tsang S, Davis RB. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006, 113:2733-2743. 10.1161/CIRCULATIONAHA.105.570648, 16754804.
107. Larose E, Rodes-Cabau J, Pibarot P, Rinfret S, Proulx G, Nguyen CM, Dery JP, Gleeton O, Roy L, Noel B, Barbeau G, Rouleau J, Boudreault JR, Amyot M, De Larochelliere R, Bertrand OF. Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance. J Am Coll Cardiol 2010, 55:2459-2469. 10.1016/j.jacc.2010.02.033, 20510213.
108. Lund GK, Stork A, Muellerleile K, Bansmann MP, Schlichting U, Mu M, Adam G, Meinertz T. Prediction of left ventricular remodeling and analysis of infarct resorption in patients with reperfused myocardial infarcts by using contrast-enhanced MR imaging. Radiology 2007, 245:95-104. 10.1148/radiol.2451061219, 17885184.
109. Wu E, Ortiz JT, Tejedor P, Lee DC, Kansal P, Carr JC, Holly TA, Klocke FJ, Bonow RO. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart 2008, 94:730-736. 10.1136/hrt.2007.122622, 18070953.
110. Lonborg J, Vejlstrup N, Kelbaek H, Holmvang L, Jorgensen E, Helqvist S, Saunamaki K, Ahtarovski KA, Botker HE, Kim WY, Clemmensen P, Engstrom T. Final infarct size measured by cardiovascular magnetic resonance in patients with ST elevation myocardial infarction predicts long-term clinical outcome: an observational study. Eur Heart J Cardiovasc Imaging 2013, 14:387-395. 10.1093/ehjci/jes271, 23178864.
111. Izquierdo M, Ruiz-Granell R, Bonanad C, Chaustre F, Gomez C, Ferrero A, Lopez-Lereu P, Monmeneu JV, Nunez J, Chorro FJ, Bodi V. Value of early cardiovascular magnetic resonance for the prediction of adverse arrhythmic cardiac events after a first noncomplicated ST-segment-elevation myocardial infarction. Circ Cardiovasc Imaging 2013, 6:755-761. 10.1161/CIRCIMAGING.113.000702, 23926195.
112. Rahimi K, Banning AP, Cheng ASH, Pegg TJ, Karamitsos TD, Channon KM, Darby S, Taggart DP, Neubauer S, Selvanayagam JB. Prognostic value of coronary revascularisation-related myocardial injury: a cardiac magnetic resonance imaging study. Heart 2009, 95:1937-1943. 10.1136/hrt.2009.173302, 19687014.
113. Nijveldt R, Beek AM, Hofman MB, Umans VA, Algra PR, Spreeuwenberg MD, Visser CA, van Rossum AC. Late gadolinium-enhanced cardiovascular magnetic resonance evaluation of infarct size and microvascular obstruction in optimally treated patients after acute myocardial infarction. J Cardiovasc Magn Reson 2007, 9:765-770. 10.1080/10976640701545008, 17891613.
114. Beek AM, Nijveldt R, van Rossum AC. Intramyocardial hemorrhage and microvascular obstruction after primary percutaneous coronary intervention. Int J Cardiovasc Imaging 2010, 26:49-55. 10.1007/s10554-009-9499-1, 2795157, 19757151.
115. Masci PG, Ganame J, Strata E, Desmet W, Aquaro GD, Dymarkowski S, Valenti V, Janssens S, Lombardi M, Van de Werf F, L'Abbate A, Bogaert J. Myocardial salvage by CMR correlates with LV remodeling and early ST-segment resolution in acute myocardial infarction. JACC Cardiovasc Imaging 2010, 3:45-51. 10.1016/j.jcmg.2009.06.016, 20129530.
116. Hahn J-Y, Song YB, Gwon H-C, Choe YH, Kim JH, Sung J, Choi S-H, Choi JH, Kim DK, Hong KP, Park JE, Lee SH. Relation of left ventricular infarct transmurality and infarct size after primary percutaneous coronary angioplasty to time from symptom onset to balloon inflation. Am J Cardiol 2008, 102:1163-1169. 10.1016/j.amjcard.2008.06.042, 18940285.
117. Nijveldt R, van der Vleuten P, Hirsch A, Beek AM, Tio R, Tijssen JGP, Piek JJ, van Rossum AC, Zijlstra F. Early electrocardiographic findings and MR imaging-verified microvascular injury and myocardial infarct size. JACC Cardiovasc Imaging 2009, 2:1187-1194. 10.1016/j.jcmg.2009.06.008, 19833308.
118. Zhao YJ, Fu XH, Ma XX, Wang DY, Dong QL, Wang YB, Li W, Xing K, Gu XS, Jiang YF. Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction. Exp Ther Med 2013, 6:479-484. 3786843, 24137212.
119. Pan W, Wang LF, Yu JH, Fan Y, Yang SS, Zhou LJ, Li Y, Li WM. Intracoronary nitroprusside in the prevention of the no-reflow phenomenon in acute myocardial infarction. Chin Med J (Engl) 2009, 122:2718-2723.